The drug, donanemab, is the latest treatment to target amyloid beta, a protein that builds up in the brain and is a signature characteristic of Alzheimer’s.
Lilly to seek FDA approval for Alzheimer’s drug that firm says slows decline
The drug, donanemab, is the latest treatment to target amyloid beta, a protein that builds up in the brain and is a signature characteristic of Alzheimer’s.